The Next Bottleneck in AI-Driven Small Molecule Discovery
AI Is Advancing Rapidly in Drug Discovery — But Is Your Data Ready?
Join leading experts from AI-first biotech, computational chemistry, and pharmaceutical R&D as they discuss how transforming fragmented scientific data into AI-ready intelligence is accelerating modern small molecule discovery workflows.
Why AI-Driven Small Molecule Discovery Needs Better Data
AI models today can generate predictions faster than ever before — but without standardized, context-rich, and integrated datasets, even the most advanced systems struggle to deliver reliable outcomes.
This exclusive panel discussion hosted on the Pistoia Alliance platform will explore why data readiness — not compute power — has become the true bottleneck in scaling AI-driven drug discovery.
Key Takeaways
- Why data readiness is becoming the biggest bottleneck in AI-driven drug discovery
- How leading biotech and pharma teams are overcoming fragmented scientific data challenges
- What it takes to build scalable, AI-ready discovery workflows and datasets
Speakers
- Gabriele Corso, CEO and Founder Boltz PBC
- Daniel Price, VP , Computational Chemistry, Nimbus Therapeutics
- Dr. Kian Tan Director, Novartis
- Dr. Govinda Bhisetti, Former VP & Head of Computational Chemistry, Cellarity
Register